QPPV.COM KNOWLEDGE ASSESSMENT

Margetuximab: Classification, Mechanism and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Margetuximab: Classification, Mechanism and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which trial-design feature is important when interpreting the SOPHIA findings for an individual patient?

The results describe a specific trial population and do not establish benefit for every chemotherapy partner or subgroup The trial established equal outcomes for every possible chemotherapy regimen The trial results apply only to patients who have never received anti-HER2 therapy The findings prove that HER2 test results are unnecessary in later-line disease

Question 2 of 10 A reduced ejection fraction is detected without symptoms. What distinction should the case assessment preserve?

An asymptomatic measurement change should be distinguished from clinical heart failure Any reduced ejection fraction should automatically be recorded as symptomatic heart failure An asymptomatic finding cannot be relevant to pharmacovigilance Symptoms should be inferred from the decision to repeat cardiac testing

Question 3 of 10 Which mechanism most directly links margetuximab binding to HER2 with immune effector activity?

HER2 binding recruits natural-killer cells through Fc interactions, which can contribute to antibody-dependent cellular cytotoxicity HER2 binding converts the antibody into a cytotoxic chemotherapy molecule inside the tumour Fc engineering causes HER2 to be released from the tumour cell surface HER2 binding blocks all immune-cell interactions with the antibody

Question 4 of 10 A patient’s disease progresses during treatment. Which approach best distinguishes this outcome from a suspected adverse drug reaction?

Document progression as an effectiveness outcome and assess any suspected adverse reactions separately, with treatment and assessment context Classify progression automatically as an adverse drug reaction caused by margetuximab Omit progression because it is not relevant to pharmacovigilance Assume progression proves the antibody was not administered

Question 5 of 10 A colleague says margetuximab’s Fc engineering guarantees a stronger clinical response than trastuzumab for every treated patient. What is the most appropriate interpretation?

The claim is justified because increased activating-receptor binding determines individual response The claim is too strong: the engineering was intended to modify immune-cell engagement, but clinical outcomes remain influenced by multiple factors The claim is justified only when margetuximab is given without chemotherapy The claim is incorrect because Fc engineering prevents antibody-dependent cellular cytotoxicity

Question 6 of 10 A pregnancy is reported during margetuximab treatment. Which information is most appropriate to collect, subject to suitable privacy protections?

Gestational timing, exposure interval, counselling and pregnancy outcome when known Only the patient’s HER2 status and tumour response Only the chemotherapy name, without the timing of exposure Pregnancy outcome alone, even if the exposure interval is unknown

Question 7 of 10 Which receptor interaction was margetuximab’s Fc engineering intended to strengthen relative to trastuzumab?

Binding to activating FcγRIIIa Binding to inhibitory FcγRIIb Binding to HER2 through the Fc region Binding to FcγRIIIa only after chemotherapy is discontinued

Question 8 of 10 When assessing a historical case, which label should guide interpretation of the product’s warnings at the time of exposure?

The label version current at the time of exposure Only the latest label, regardless of when the exposure occurred The first label ever issued, regardless of later changes A label from another jurisdiction if it contains more warnings

Question 9 of 10 Why should HER2 assay method and specimen details be retained when assessing treatment effectiveness or lack of effect?

HER2 status defines treatment eligibility, and the assay, specimen and interpretation are part of the treatment context HER2 testing determines the infusion rate for every cycle HER2 assay details replace the need to record prior anti-HER2 treatment HER2 status is relevant only for assessing pregnancy exposure

Question 10 of 10 Which administration schedule is described for margetuximab in the article?

Intravenous infusion every three weeks Daily oral administration Weekly subcutaneous injection A single intramuscular dose before chemotherapy

Margetuximab: Classification, Mechanism and Pharmacovigilance — Knowledge Assessment

Cookie Settings